<img src="https://ml.globenewswire.com/Resource/Download/1b0f858f-4f7f-4f50-b691-a25307283fb5?size=2" nborder="0" align="left" hspace="5" vspace="5" title="AnavexLogoR-Transparent @3x.png" alt="Anavex Life Sciences Corp."/>NEW YORK, Sept. 08, 2026 <a href="https://www.globenewswire.com" target="_blank">(GLOBE NEWSWIRE)</a> -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for central nervous system diseases with high unmet medical needs, today announced it will host a conference call at 4:00 PM ET on Wednesday, September 9, 2026, during which Interim CEO Terrie Kellmeyer, Ph.D., will discuss the Company’s clinical development strategy and priorities. Anavex Investor Call Information: <ul type="disc"><li>A link to the live <a href="https://www.globenewswire.com/Tracker?data=K-uBZcwYe9LSOy9TFB4Qo5Hh2lqpcdC1IHefwDdHwJ0jDg0uMg7H_YKT8DqETfz4t2AZVkvMtMrAnnByhruqXi-88XK1fqqQarkkWt6_5OM=" rel="nofollow" target="_blank" title="webcast">webcast</a> of the conference call will be available on Anavex’s investor relations website at <a href="https://www.globenewswire.com/Tracker?data=aoczEna-Rkez9YvUdgHVIpIxEL3CH0iRw_Zt_uEnqgOREAgVQZcvJVmg3jxFLWQAPUcf1sw7IyyozMRRyn7shEYb64RDFkN7uNFinle4GU8=" rel="nofollow" target="_blank" title="anavex.com/investors">anavex.com/investors</a>.</li><li>The conference call can also be accessed by dialing 1-866-777-2509 for participants in the U.S. and Canada or 1-412-317-5413 for international participants. Participants should ask to join the Anavex call.</li><li>A replay of the conference call will be available at <a href="https://www.globenewswire.com/Tracker?data=aoczEna-Rkez9YvUdgHVIpIxEL3CH0iRw_Zt_uEnqgPgj4zv7q7Hgfz1xDZ1PxJa7gc1xRQiEXYR10_dTtNL_-K9bsjnqYsrqWR-uqebSU8=" rel="nofollow" target="_blank" title="anavex.com/investors">anavex.com/investors</a> shortly after the end of the call. </li></ul> The Company is now current on its financial reporting obligations with the Securities and Exchange Commission and, on September 2, 2026, officially regained compliance with NASDAQ listing rules as a result of filing its outstanding Form 10-Qs for the second and third fiscal quarters for 2026. About Anavex Life Sciences Corp. Anavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded clinical stage biopharmaceutical company engaged in the development of novel therapeutics for the treatment of central nervous system diseases with high unmet medical need. Further information is available at <a href="https://www.globenewswire.com/Tracker?data=4Dn91usBy0j3KiVVoTIWy2Oz2Iq91WsiOpUx8cpEh4omq0NLeTtgUFbIANu5yzobSqz20RWHV0R6V5sQe9_4Yw==" rel="nofollow" target="_blank" title="www.anavex.com">www.anavex.com</a>. Investor Relations &amp; Media Contact: SCR Partners, LLC Alex Arzeno Tel: 203-550-3972 Email: alex@scr-ir.com Tripp Sullivan Tel: 615-942-7077 Email: tsullivan@scr-ir.com Company Contact: Sandra Boenisch Principal Financial Officer Anavex Life Sciences Corp. Tel: 1-844-689-3939 Email: <a href="https://www.globenewswire.com/Tracker?data=XmwitS9_1HKYlKWd2Oyfgd3ayelJ4CpXC1fh4NdOXhk6KJS2DZ3SsdXiiHNVOb-fWakzYU8DNfDupHbSrufLsJJ54jvek0LWqL4NOYrRt5w=" rel="nofollow" target="_blank" title="ir@anavexcorp.com">ir@anavexcorp.com</a> <img alt="" src='https://ml.globenewswire.com/media/MjFjNGM5ODEtMDU1Ny00NDVkLTg5ZjktOWI5OTMwZWJiNTNmLTEwMzExNzYtMjAyNi0wOS0wOC1lbg==/tiny/Anavex-Life-Sciences-Corp-.png' referrerpolicy='no-referrer-when-downgrade' />

Anavex Life Sciences to Host Investor Call on Wednesday, September 9, 2026, at 4:00 PM ET

Latest news from the world of business and finance – both local and global

MONEY FM 89.3 is Singapore's first and only Business and Personal Finance station, featuring local and international business and financial news.

MONEY FM 89.3

Discover newsletters from our DJs on LinkedIn